Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Oxytocin

Pitocin, Syntocinon

Quick Stats
Studies 93
Trials 100
Completed NA INTERVENTIONAL NCT04715737

Differential Effects of Vasopressin and Oxytocin on Attention Control

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

The main aim of the present study is to investigate whether intranasal vasopressin (20IU) and oxytocin (24IU) have differential effects on attention control in a social-emotional saccade/antisaccade eye-tracking paradigm.

Detailed Description

Previous studies have demonstrated intranasal vasopressin and oxytocin's divergent effects on social behavior and emotion processing such as empathy and negative emotion processing, however, it remains unclear whether vasopressin and oxytocin treatment would have differential effects on attention processing to social stimuli. Based on the previous registered studies (ClinicalTrials.gov ID: NCT04493554 and NCT03486925) from our group using a validated emotional anti-saccade task with social stimuli (emotional faces) and non-social stimuli (oval shape) have separately explored intranasal vasopressin and oxytocin's modulatory effects on attention processing, the present study aims to conduct a secondary analysis of the previously acquired data to directly compare vasopressin and oxytocin's effects on attention control to social emotional stimuli. To this end data from subjects who underwent intranasal oxytocin administration (n = 33; NCT03486925) will be compared with data from subjects who underwent intranasal vasopressin or placebo administration (n = 39, or 45 respectively; NCT04493554). To further control for non-treatment related factors the intranasal placebo groups from the previous studies (ClinicalTrials.gov ID: NCT04493554 and NCT03486925) will be compared with respect to primary and secondary outcome measures of the trial, in particular general and emotion-specific effects on attentional control.

Interventions

Name: Vasopressin
Type: DRUG
Description: Administration of vasopressin (20IU) intranasally
Name: Oxytocin
Type: DRUG
Description: Administration of oxytocin (24IU) intranasally
Name: Placebo
Type: DRUG
Description: Administration of placebo intranasally

Primary Outcomes

Measure: Differential effects of intranasal vasopressin and oxytocin administration on saccade/antisaccade latencies towards social (facial) versus non-social (shape) stimuli
TimeFrame: Time Frame: 45 minutes - 100 minutes after treatment
Description: Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin, oxytocin and placebo treatment conditions
Measure: Differential effects of intranasal vasopressin and oxytocin administration on error rates of saccade/antisaccade for social (facial) versus non-social (shape) stimuli
TimeFrame: Time Frame: 45 minutes - 100 minutes after treatment
Description: Comparison between social-specific error rates of saccade/antisaccade between the vasopressin, oxytocin and placebo treatment conditions

Trial Information

NCT ID

NCT04715737

Status

Completed

Study Type

INTERVENTIONAL

Phases

NA

Sponsor

University of Electronic Science and Technology of China

Last Updated

December 15, 2025